These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

882 related items for PubMed ID: 15918104

  • 1. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ, Jacobsen P, Rossing K, Boomsma F, Parving HH.
    Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
    [Abstract] [Full Text] [Related]

  • 2. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 4. Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.
    Schjoedt KJ, Lajer M, Andersen S, Tarnow L, Rossing P, Parving HH.
    Scand J Clin Lab Invest; 2006 Sep; 66(3):173-80. PubMed ID: 16714246
    [Abstract] [Full Text] [Related]

  • 5. Dual blockade of the renin-angiotensin system in diabetic nephropathy.
    Wade VL, Gleason BL.
    Ann Pharmacother; 2004 Sep; 38(7-8):1278-82. PubMed ID: 15187210
    [Abstract] [Full Text] [Related]

  • 6. [Risk and prevention of diabetic nephropathy].
    Ravera M, Re M, Deferrari G.
    G Ital Nefrol; 2007 Sep; 24 Suppl 38():13-9. PubMed ID: 17922442
    [Abstract] [Full Text] [Related]

  • 7. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L, Kocks MJ, Laverman GD, Navis G.
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [Abstract] [Full Text] [Related]

  • 8. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
    Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH.
    Kidney Int; 2003 May; 63(5):1874-80. PubMed ID: 12675866
    [Abstract] [Full Text] [Related]

  • 9. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
    Dalla Vestra M, Simioni N, Masiero A.
    Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
    [Abstract] [Full Text] [Related]

  • 10. [The angiotensin II inhibition escape phenomenon in patients with type 2 diabetes and diabetic nephropathy].
    Shamkhlova MSh, Trubitsyna NP, Katsaia GV, Goncharov NP, Malysheva NM, Il'in AV, Nikankina LV, Koshel' LV, Shestakova MV.
    Ter Arkh; 2008 Dec; 80(1):49-52. PubMed ID: 18326228
    [Abstract] [Full Text] [Related]

  • 11. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D.
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [Abstract] [Full Text] [Related]

  • 12. Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy.
    Seki N, Hashimoto N, Suzuki Y, Yagui K, Saito Y.
    Diabetes Res Clin Pract; 2006 May; 72(2):135-41. PubMed ID: 16290123
    [Abstract] [Full Text] [Related]

  • 13. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
    Kolasinska-Malkowska K, Filipiak KJ, Gwizdala A, Tykarski A.
    Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
    [Abstract] [Full Text] [Related]

  • 14. Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?
    Kalaitzidis R, Bakris G.
    Postgrad Med; 2009 Mar; 121(2):77-88. PubMed ID: 19332965
    [Abstract] [Full Text] [Related]

  • 15. [Multilevel blockade of the renin-angiotensin-aldosterone system in the treatment of diabetic nephropathy].
    Fronczyk A, Majkowska L.
    Przegl Lek; 2007 Mar; 64(2):81-5. PubMed ID: 17892038
    [Abstract] [Full Text] [Related]

  • 16. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA.
    Am J Cardiol; 2007 Aug 06; 100(3A):45J-52J. PubMed ID: 17666198
    [Abstract] [Full Text] [Related]

  • 17. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection.
    Abuissa H, O'Keefe J.
    Diabetes Obes Metab; 2008 Dec 06; 10(12):1157-66. PubMed ID: 18494810
    [Abstract] [Full Text] [Related]

  • 18. Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II).
    Jacobsen PK.
    J Renin Angiotensin Aldosterone Syst; 2005 Sep 06; 6(2):55-68. PubMed ID: 16470484
    [Abstract] [Full Text] [Related]

  • 19. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
    Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J.
    Diabet Med; 2007 May 06; 24(5):486-93. PubMed ID: 17367311
    [Abstract] [Full Text] [Related]

  • 20. Emerging therapeutic strategies in diabetic nephropathy.
    Ravera M, Re M, Weiss U, Deferrari L, Deferrari G.
    J Nephrol; 2007 May 06; 20 Suppl 12():S23-32. PubMed ID: 18050139
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.